NIBEC CO., LTD. Logo

NIBEC CO., LTD.

Biotech CDMO creating regenerative products with peptide and biomaterial technologies.

138610 | KO

Overview

Corporate Details

ISIN(s):
KR7138610001
LEI:
Country:
South Korea
Address:
충청북도 진천군 이월면 밤디길 116 이월전기전자농공1단지, 진천군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NIBEC Co., Ltd. is a biotechnology company focused on developing innovative healthcare solutions through regenerative medicine. The company specializes in the research, development, and commercialization of products based on its core expertise in bioactive peptide technology and advanced biomaterials. Its primary offerings include tissue regenerative products, such as dental bone grafts and collagen-based materials, as well as peptide-based smart materials and bio-fusion products for medical applications. Additionally, NIBEC operates as a Contract Development and Manufacturing Organization (CDMO), providing cGMP-compliant custom peptide synthesis and manufacturing services to the pharmaceutical and biotech sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 903.3 KB
2025-08-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-06-04 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.5 KB
2025-05-28 00:00
M&A Activity
투자판단관련주요경영사항 (NP201 기술이전의 건)
Korean 13.8 KB
2025-05-22 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.1 KB
2025-05-22 00:00
Share Issue/Capital Change
전환가액의조정
Korean 12.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 815.7 KB
2025-04-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.2 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 993.7 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 18.1 KB
2025-03-20 00:00
Audit Report / Information
[기재정정]감사보고서제출
Korean 21.2 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 101.6 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 92.6 KB

Automate Your Workflow. Get a real-time feed of all NIBEC CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIBEC CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIBEC CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.